Please assess the completion status of the following clinical trial:

Trial Title: Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients ages 0 to 6 months who do need meet the criteria at the initial appointment for supraglottoplasty~* Seen in University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh (CHP) Otolaryngology Department~* Laryngomalacia without prolonged (\>20 seconds) cyanosis, apnea, nor failure to thrive.~Exclusion Criteria:~* Children over the age of 6 months old will be excluded from participation.~* Premature infants (\<37 weeks gestation)~* Patients with lung disease.~* Laryngomalacia with prolonged (\>20 seconds) cyanosis, apnea, and failure to thrive~* Sleep induced laryngomalacia~* Patients with craniofacial abnormalities~* Patients with a syndrome~* Patients with additional airway abnormalities, seen before or at consult~* Patients with symptoms that necessitate surgery~* Patients with a prior cardiac surgery~* Patients with AST prescribed prior to the initial otolaryngology consult.

- Gender: ALL
- Minimum Age: 0 Months
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Speech Language Therapy Alone (Type: EXPERIMENTAL): Patients in this group will receive a routine swallowing evaluation by a speech language pathologist. Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
- Speech Language Therapy and Acid Suppression Therapy (Type: ACTIVE_COMPARATOR): Patients in this group will receive a routine swallowing evaluation by a speech language pathologist and famotidine (acid suppression therapy). Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.

Based on this trial design, predict the completion outcome and termination type (if applicable).